https://charts.traderzeitung.de/phases/US68622P1093
string(1421) "{"isin":"US68622P1093","name":"ORIC Pharmaceuticals Inc","stock_id_xnas":12004298,"stock_id_xnys":null,"generated_at":"2026-08-21 11:14:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.93,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":14.65,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":5.1687},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.88,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-5.256},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":13.87,"close_at":"2026-08-20 22:00:00","complete":true,"perf_pct":-0.072}]}]}"
ORIC Pharmaceuticals Aktie News & Nachrichten
Trading-Room

ORIC Pharmaceuticals Aktie News & Nachrichten

[WKN: A2P208 | Symbol: ORIC]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

ORIC Pharmaceuticals

TOP-5-Kursziele der Analysten am 15.01.26

Rapid Micro Biosystems [US75340L1044] Lake Street bestätigt Buy-Rating mit 8 USD (120 % Kurspotenzial)...

ORIC Pharmaceuticals Inc. (ORIC): H.C. Wainwright sieht 172 % Kurspotenzial!

ORIC Pharmaceuticals Inc. (ORIC) ist ein biopharmazeutisches Unternehmen, das sich auf Therapien zur...

TOP-5-Kursziele der Analysten am 06.02.25

ArcelorMittal [LU1598757687]: Jefferies belässt Einstufung auf "Buy" mit Kursziel 33 Euro (29 % Kurspotenzial)...

ORIC Pharmaceuticals (ORIC): H.C. Wainwright sieht 111 % Kurspotenzial nach Phase 1b-Daten von ORIC-944

Bei den Biotechnologiekonzern wurden im letzten Jahr Hoffnungen auf eine M&A-Welle ausgelöst. Führende...

  • ‹
  • 1
  • ›
ORIC Pharmaceuticals Nachrichtenticker öffnen
MT Newswires 14.07.2026 23:08 Uhr

ORIC Pharmaceuticals beginnt Phase-3-Studie mit Rinzimetostat bei metastasiertem Prostatakrebs

05:07 PM EDT, 07/14/2026 (MT Newswires) -- ORIC Pharmaceuticals (ORIC) teilte am Dienstag mit, dass es die globale Phase-3-Studie Himalayas-1 zur Bewe